Research programme: heat-activated liposome encapsulated cancer therapeutics - Celsion Corporation

Drug Profile

Research programme: heat-activated liposome encapsulated cancer therapeutics - Celsion Corporation

Alternative Names: Liposomal carboplatin; Liposomal docetaxel

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celsion Corporation
  • Developer Celsion Corporation; Duke University Medical Center
  • Class Platinum complexes; Small molecules; Taxanes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV, Infusion)
  • 03 Sep 2010 Preclinical development of heat-activated liposomal docetaxel and liposomal carboplatin is ongoing in the USA (IV)
  • 03 Sep 2010 Celsion Corporation receives SBIR grant from the National Institutes of Health for heat-activated liposomal carboplatin development in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top